Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota

Overview

Journal ACR Open Rheumatol

Date 2024 Apr 23

PMID 38653503

Authors

Kristofer Andreasson

Tor Olofsson

Venu Lagishetty

Zaid Alrawi

Eline Klaassens

Savanne Holster

Roger Hesselstrand

Jonathan P Jacobs

Johan K Wallman

Elizabeth R Volkmann

Affiliations

Soon will be listed here.

Abstract

Objective: Emerging research suggests that rheumatoid arthritis (RA) is associated with intestinal dysbiosis. This prospective pilot study evaluates changes in intestinal microbial composition in patients with RA initiating treatment with either methotrexate (MTX) or a tumor necrosis factor inhibitor (TNFi).

Methods: Consecutive patients, fulfilling the 2010 American College of Rheumatology/EULAR classification criteria for RA, who started treatment with either MTX or TNFi delivered a stool sample upon initiation of immunosuppression and 3 months later. A 16S ribosomal RNA gene-based validated microbiota test (GA-map Dysbiosis Index Score [DIS], Genetic Analysis, Oslo, Norway) was used to evaluate for the presence and degree of dysbiosis. Fecal levels of Prevotella copri (P. copri) were analyzed by custom-made quantitative polymerase chain reaction. Changes in microbial composition were analyzed in relation to changes in disease activity, as measured by the disease activity score based on 28-joint counts, using C-reactive protein.

Results: At baseline, dysbiosis was present in 33 of 50 (66%) participants and more common in participants with more than 2 years of disease duration (P = 0.019). At the 3-month follow-up, 27 of 50 (54%) were good treatment responders and the DIS had improved in 14 of 50 (28%). Participants initiating TNFi more often exhibited improvement in the DIS compared with those initiating MTX (P = 0.031). P. copri was identified in 32 of 50 (64%) at baseline. An improvement in disease activity score based on 28-joint counts, using C-reactive protein was associated with a simultaneous decrease in P. copri abundance (r = 0.30, P = 0.036).

Conclusion: This study affirms that dysbiosis is a feature of RA. Although patients were not randomized to MTX or TNFi, the findings suggest that specific therapies may differentially modulate the gastrointestinal microbiota in RA. The association between P. copri and treatment response requires further study.

References

Chen J, Wright K, Davis J, Jeraldo P, Marietta E, Murray J . An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016; 8(1):43. PMC: 4840970. DOI: 10.1186/s13073-016-0299-7. View

Casen C, Vebo H, Sekelja M, Hegge F, Karlsson M, Ciemniejewska E . Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015; 42(1):71-83. PMC: 5029765. DOI: 10.1111/apt.13236. View

Seifert J, Bemis E, Ramsden K, Lowell C, Polinski K, Feser M . Association of Antibodies to Prevotella copri in Anti-Cyclic Citrullinated Peptide-Positive Individuals At Risk of Developing Rheumatoid Arthritis and in Patients With Early or Established Rheumatoid Arthritis. Arthritis Rheumatol. 2022; 75(4):507-516. PMC: 10065886. DOI: 10.1002/art.42370. View

Kim M, Kim J, Kang M, Won M, Hong S, Her Y . Reduced Fecal Calprotectin and Inflammation in a Murine Model of Atopic Dermatitis Following Probiotic Treatment. Int J Mol Sci. 2020; 21(11). PMC: 7312066. DOI: 10.3390/ijms21113968. View

Scher J, Sczesnak A, Longman R, Segata N, Ubeda C, Bielski C . Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. 2013; 2:e01202. PMC: 3816614. DOI: 10.7554/eLife.01202. View

Waugh N, Cummins E, Royle P, Kandala N, Shyangdan D, Arasaradnam R . Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013; 17(55):xv-xix, 1-211. PMC: 4781415. DOI: 10.3310/hta17550. View

Chriswell M, Lefferts A, Clay M, Hsu A, Seifert J, Feser M . Clonal IgA and IgG autoantibodies from individuals at risk for rheumatoid arthritis identify an arthritogenic strain of . Sci Transl Med. 2022; 14(668):eabn5166. PMC: 9804515. DOI: 10.1126/scitranslmed.abn5166. View

Artacho A, Isaac S, Nayak R, Flor-Duro A, Alexander M, Koo I . The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis. Arthritis Rheumatol. 2020; 73(6):931-942. PMC: 11293279. DOI: 10.1002/art.41622. View

Alpizar-Rodriguez D, Lesker T, Gronow A, Gilbert B, Raemy E, Lamacchia C . in individuals at risk for rheumatoid arthritis. Ann Rheum Dis. 2019; 78(5):590-593. DOI: 10.1136/annrheumdis-2018-214514. View

10.

Dai Q, Xia X, He C, Huang Y, Chen Y, Wu Y . Association of anti-TNF-α treatment with gut microbiota of patients with ankylosing spondylitis. Pharmacogenet Genomics. 2022; 32(7):247-256. PMC: 9351697. DOI: 10.1097/FPC.0000000000000468. View

11.

Wells G, Becker J, Teng J, Dougados M, Schiff M, Smolen J . Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on.... Ann Rheum Dis. 2008; 68(6):954-60. PMC: 2674547. DOI: 10.1136/ard.2007.084459. View

12.

Wei S, Bahl M, Dahl Baunwall S, Lodberg Hvas C, Rask Licht T . Determining Gut Microbial Dysbiosis: a Review of Applied Indexes for Assessment of Intestinal Microbiota Imbalances. Appl Environ Microbiol. 2021; 87(11). PMC: 8208139. DOI: 10.1128/AEM.00395-21. View

13.

Scher J, Nayak R, Ubeda C, Turnbaugh P, Abramson S . Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. Nat Rev Rheumatol. 2020; 16(5):282-292. PMC: 11221369. DOI: 10.1038/s41584-020-0395-3. View

14.

Svedlund J, Sjodin I, DOTEVALL G . GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988; 33(2):129-34. DOI: 10.1007/BF01535722. View

15.

Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9):2569-81. DOI: 10.1002/art.27584. View

16.

Pianta A, Arvikar S, Strle K, Drouin E, Wang Q, Costello C . Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints. J Clin Invest. 2017; 127(8):2946-2956. PMC: 5531397. DOI: 10.1172/JCI93450. View

17.

Klareskog L, Ronnelid J, Saevarsdottir S, Padyukov L, Alfredsson L . The importance of differences; On environment and its interactions with genes and immunity in the causation of rheumatoid arthritis. J Intern Med. 2020; 287(5):514-533. DOI: 10.1111/joim.13058. View

18.

Mandl T, Marsal J, Olsson P, Ohlsson B, Andreasson K . Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity. Arthritis Res Ther. 2017; 19(1):237. PMC: 5655865. DOI: 10.1186/s13075-017-1446-2. View

19.

Wang H, Ong E, Kao J, Sun D, He Y . Reverse Microbiomics: A New Reverse Dysbiosis Analysis Strategy and Its Usage in Prediction of Autoantigens and Virulent Factors in Dysbiotic Gut Microbiomes From Rheumatoid Arthritis Patients. Front Microbiol. 2021; 12:633732. PMC: 7947680. DOI: 10.3389/fmicb.2021.633732. View

20.

Picchianti-Diamanti A, Panebianco C, Salemi S, Sorgi M, Di Rosa R, Tropea A . Analysis of Gut Microbiota in Rheumatoid Arthritis Patients: Disease-Related Dysbiosis and Modifications Induced by Etanercept. Int J Mol Sci. 2018; 19(10). PMC: 6213034. DOI: 10.3390/ijms19102938. View